LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Listă Acțiuni・AnaptysBio Inc

AnaptysBio Inc

Închisă

SectorSănătate

51.39 1.86

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

49.8

Maxim

52.53

Indicatori cheie
By Trading Economics
Venit	-102M -53M
Vânzări	-83M 26M
EPS	-1.843
Marjă de profit	-206.934
Angajați	104
EBITDA	-102M -34M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+43.93% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-430M 1.5B
Deschiderea anterioară	49.53
Închiderea anterioară	51.39

Sentimentul știrilor

By Acuity

93%

319 / 344 Clasament în Healthcare

AnaptysBio Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 iun. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 iun. 2026, 15:41 UTC

Principalele dinamici ale pieței

American Battery Shares Jump on Energy Department Victory

8 iun. 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 iun. 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 iun. 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 iun. 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 iun. 2026, 21:57 UTC

Achiziții, Fuziuni, Preluări

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 iun. 2026, 21:56 UTC

Achiziții, Fuziuni, Preluări

Salesforce Agrees to Buy m3ter

8 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 iun. 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 iun. 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 iun. 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 iun. 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 iun. 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 iun. 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 iun. 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 iun. 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 iun. 2026, 16:55 UTC

Achiziții, Fuziuni, Preluări

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 iun. 2026, 16:54 UTC

Achiziții, Fuziuni, Preluări

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 iun. 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 iun. 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 iun. 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 iun. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 iun. 2026, 16:03 UTC

Achiziții, Fuziuni, Preluări

Orange Bought Stake From Lorca

8 iun. 2026, 16:01 UTC

Achiziții, Fuziuni, Preluări

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 iun. 2026, 16:01 UTC

Achiziții, Fuziuni, Preluări

Orange Acquires 100% Ownership of MasOrange

8 iun. 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 iun. 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 iun. 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 iun. 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparație

Modificare preț

AnaptysBio Inc Așteptări

Obiectiv de preț

By TipRanks

43.93% sus

Prognoză pe 12 luni

Medie 72.5 USD 43.93%

Maxim 93 USD

Minim 50 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAnaptysBio Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor AnaptysBio Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

319 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.